Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective: Automated insulin delivery (AID) may benefit individuals with long-standing type 1 diabetes where frequent exposure to hypoglycemia impairs counterregulatory responses. This study assessed the effect of 18 months AID on hypoglycemia avoidance and glucose counterregulatory responses to insulin-induced hypoglycemia in long-standing type 1 diabetes complicated by impaired awareness of hypoglycemia. Methods: Ten participants mean ± standard deviation age 49 ± 16 and diabetes duration 34 ± 16 years were initiated on AID. Continuous glucose monitoring was paired with actigraphy to assess awake- and sleep-associated hypoglycemia exposure every 3 months. Hyperinsulinemic hypoglycemic clamp experiments were performed at baseline, 6, and 18 months postintervention. Hypoglycemia exposure was reduced by 3 months, especially during sleep, with effects sustained through 18 months ( P ≤ 0.001) together with reduced glucose variability ( P < 0.01). Results: Hypoglycemia awareness and severity scores improved ( P < 0.01) with severe hypoglycemia events reduced from median (interquartile range) 3 (3–10) at baseline to 0 (0–1) events/person·year postintervention ( P = 0.005). During the hypoglycemic clamp experiments, no change was seen in the endogenous glucose production (EGP) response, however, peripheral glucose utilization during hypoglycemia was reduced following intervention [pre: 4.6 ± 0.4, 6 months: 3.8 ± 0.5, 18 months: 3.4 ± 0.3 mg/(kg·min), P < 0.05]. There were increases over time in pancreatic polypeptide (Pre:62 ± 29, 6 months:127 ± 44, 18 months:176 ± 58 pmol/L, P < 0.01), epinephrine (Pre: 199 ± 53, 6 months: 332 ± 91, 18 months: 386 ± 95 pg/mL, P = 0.001), and autonomic symptom (Pre: 6 ± 2, 6 months: 6 ± 2, 18 months: 10 ± 2, P < 0.05) responses. Conclusions: AID led to a sustained reduction of hypoglycemia exposure. EGP in response to insulin-induced hypoglycemia remained defective, however, partial recovery of glucose counterregulation was evidenced by a reduction in peripheral glucose utilization likely mediated by increased epinephrine secretion and, together with improved autonomic symptoms, may contribute to the observed clinical reduction in hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“Nevertheless, from 3 months onward, the median percentage of time-in-range (70–180 mg/dL) exceeded the consensus target of 70%, well above the target of >50% recommended in those at high risk of severe hypoglycemia.(49) This change was predominantly driven by the early improvement in hypoglycemia avoidance on AID inte…”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 2×
“26 30 In individuals with type 1 diabetes and either IAH or a recent severe hypoglycemia event, use of PLGS for 6 months reduced time spent with hypoglycemia by > 50% and reduced severe hypoglycemic events sixfold compared to insulin pump therapy without real-time CGM. 31 Moreover, PLGS use was…”
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation
Rizza, R. A., Cryer, P. E., & Gerich, J. E. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109464 · Cited by 421 · cited 1×
“Loss of the glucagon response to hypoglycemia early in type 1 diabetes pathogenesis leads to the reliance on epinephrine to increase EGP (predominantly hepatic) and reduce peripheral glucose utilization required for physiologic glucose counterregulation.(47,48) In long-standing type 1 diabetes the magnitude of the epi…”
Fanelli, C. G., Epifano, L., Rambotti, A. M., Pampanelli, S., Di Vincenzo, A., Modarelli, F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993) · Diabetes · doi:10.2337/diab.42.11.1683 · Cited by 398
Cited by
The role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
De Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06366-x · Cited by 27
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13
Metadata
- Authors
- Flatt, A. J., Peleckis, A. J., Dalton-Bakes, C., Nguyen, H.-L., Ilany, S., Matus, A., Malone, S. K., Goel, N., Jang, S., Weimer, J., Lee, I., & Rickels, M. R.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2023-05-01
- Volume
- 25
- Issue
- 5
- Pages
- 302-314
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W4319812608
- Cited by
- 39
- References
- 22
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.